Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; Head and Neck Surgery & Forensic Dissection Research Center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
World Neurosurg. 2022 Feb;158:e645-e653. doi: 10.1016/j.wneu.2021.11.035. Epub 2021 Nov 14.
Olfactory neuroblastoma (ONB) is a rare malignant tumor arising in the upper nasal cleft. Rarely, ONB may originate in ectopic sites and the impact of this on prognosis and treatment strategies continues to be debated.
A retrospective analysis was undertaken of patients with ectopic ONB treated between 2000 and 2020 in a tertiary-care referral center for skull base tumors. Three patients were included in this analysis: a 37-year-old woman with ONB arising from the bulla ethmoidalis; a 28-year-old man with inappropriate secretion of antidiuretic hormone caused by a maxillary sinus ONB; and a 41-year-old man with lacrimal sac ONB. Preoperative workup, surgical approach, adjuvant treatments and postoperative surveillance were analyzed. Relevant literature published between 2000 and January 2021 was fully reviewed to investigate oncologic outcomes and delineate the standard of care for such rare tumors.
All patients were treated via endoscopic endonasal resection with radical intent, followed by adjuvant treatments when required. No recurrences of disease were observed after a mean follow-up time of 32 months (range, 12-60 months). Data emerging from the literature suggest that a multidisciplinary treatment approach, including free-margins surgical resection followed by adjuvant radiotherapy or radiochemotherapy, is recommended. Olfactory bulb and dura preservation should be attempted whenever feasible.
Endoscopic endonasal surgery should be preferred, when possible, to achieve complete excision to minimize patients' morbidity. The ectopic site of origin affects prognosis and should be considered when selecting the appropriate multimodal treatment strategy.
嗅神经母细胞瘤(ONB)是一种罕见的发生在上鼻道的恶性肿瘤。ONB 很少起源于异位部位,其对预后和治疗策略的影响仍存在争议。
对 2000 年至 2020 年期间在一家颅底肿瘤三级转诊中心接受治疗的异位 ONB 患者进行回顾性分析。本研究纳入了 3 名患者:1 名 37 岁女性,ONB 起源于筛泡;1 名 28 岁男性,因上颌窦 ONB 导致抗利尿激素不适当分泌;1 名 41 岁男性,患有泪囊 ONB。分析了术前检查、手术方法、辅助治疗和术后监测。全面回顾了 2000 年至 2021 年 1 月期间发表的相关文献,以研究肿瘤学结果并阐明此类罕见肿瘤的治疗标准。
所有患者均通过内镜经鼻入路行根治性切除术,必要时辅助治疗。平均随访 32 个月(12-60 个月)后未观察到疾病复发。文献中的数据表明,建议采用多学科治疗方法,包括边缘无肿瘤残留的手术切除,然后根据需要进行辅助放疗或放化疗。只要可行,应尝试保留嗅球和硬脑膜。
如果可能,应首选内镜经鼻手术以实现完全切除,从而最大限度地降低患者的发病率。起源于异位部位会影响预后,在选择适当的多模式治疗策略时应予以考虑。